The co-analysis of tumor mutational load and immune infiltration revealed ADRB1 as a possible biomarker for breast cancer.[25] As a result, activating ADRB1 may protect against neuroinflammatory disorders.[26] In human tumor samples, the expression of ADRB2 was elevated in tumor tissues and linked favorably with tumor size, histological grade, lymph node metastasis, and clinical stage. Here, ADRB2 is linked to neoplasm.